Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSORIATYK Scalp: Deucravacitinib in Moderate-to-Severe Scalp Psoriasis
2022-000797-26Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: ss-PGA 0/1 response at Week 16. Started Aug 2022; status: completed.
02
Drugs
deucravacitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2022-000797-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000797-26.